Beyond Air
Update in progressXAIR (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
Beyond Air is a commercial-stage medical device and biopharma company developing the Lungfit nitric oxide generator and delivery platform. It operates in three segments: Beyond Air, Beyond Cancer, and NeuroNos. Products include Lungfit PH for persistent pulmonary hypertension of the newborn, LungFit PRO for viral lung infections, and LungFit GO for home treatment of NTM. It also develops UNO for tumors and a selective nNOS inhibitor for neurological conditions, with a Yissum collaboration. Formerly AIT Therapeutics, renamed Beyond Air in 2019. Founded 2011; headquartered in Garden City, NY.
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.14
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.33
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.16
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Robert Scott Goodman
- Founded2011
- Employees54
- Websitewww.beyondair.net
Identifiers
- ISINUS08862L1035
- FIGIBBG00B4QYL72
- LEI549300GFTTTXX5728360
- CUSIP08862L103
- CIK0001641631